Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma.

@article{Mamelak2006PhaseIS,
  title={Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma.},
  author={Adam N. Mamelak and Steven S. Rosenfeld and Richard D. Bucholz and Andrew Raubitschek and Louis Burt Nabors and John Fiveash and Sui Shen and M. B. Khazaeli and David Colcher and An Liu and Medhat M. Osman and Barton L. Guthrie and Susan Schade-Bijur and Diana M Hablitz and Vernon Leon Alvarez and Matthew A. Gonda},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 22},
  pages={
          3644-50
        }
}
  • A. Mamelak, S. Rosenfeld, +13 authors M. Gonda
  • Published 2006
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE TM-601 binds to malignant brain tumor cells with high affinity and does not seem to bind to normal brain tissue. Preclinical studies suggest that iodine-131 (131I) -TM-601 may be an effective targeted therapy for the treatment of glioma. We evaluated the safety, biodistribution, and dosimetry of intracavitary-administered 131I-TM-601 in patients with recurrent glioma. PATIENTS AND METHODS Eighteen adult patients (17 with glioblastoma multiforme and one with anaplastic astrocytoma… Expand

Paper Mentions

Interventional Clinical Trial
The purpose of this study is to evaluate the safety and effectiveness of 131I-TM601 in the treatment of adult patients with progressive or recurrent malignant gliomas.  
ConditionsAstrocytoma, GBM, Glioblastoma Multiforme, (+2 more)
InterventionDrug
Interventional Clinical Trial
The purpose of this study is to evaluate the safety and biologically active dose of TM-601 in adult patients with recurrent malignant glioma.  
ConditionsAstrocytoma, GBM, Glioblastoma Multiforme, (+2 more)
InterventionDrug
Interventional Clinical Trial
This drug is being developed to treat a type of brain cancer, glioma. This study was developed to evaluate the safety, time to disease progression and survival rates after… Expand
ConditionsAnaplastic Astrocytoma, GBM, Glioblastoma Multiforme, (+3 more)
InterventionDrug
131I-TM-601 SPECT imaging of Human Glioma
TLDR
131I-TM601 provides a reliable estimate for primary tumor extent and further modification of this radio-peptide with better imaging isotopes such as 123I (SPECT) or 124I (PET), may provide clinicians with an important tool for determining tumors extent and differentiating regions of viable tumor from necrosis. Expand
Phase 1 Safety, Pharmacokinetics, and Fluorescence Imaging Study of Tozuleristide (BLZ-100) in Adults With Newly Diagnosed or Recurrent Gliomas.
TLDR
A phase 1 dose-escalation study to characterize the safety, pharmacokinetics, and fluorescence imaging of tozuleristide in adults with suspected glioma suggests that tozulumistide imaging may be useful for FGS of gliomas. Expand
Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas
TLDR
A locoregional single dose of 188Re-labelled nimotuzumab of approximately 370 MBq could be used safely in the routine treatment of patients suffering with high-grade gliomas and needs to be evaluated in a phase II clinical trial. Expand
Intracavitary radioimmunotherapy of high-grade gliomas: present status and future developments
TLDR
Intracavitary radioimmunotherapy, in combination with radiotherapy, is discussed in the present review as a therapeutic strategy of high potential and deserves further exploration in future studies by incorporating several innovative modifications. Expand
Polymeric drug delivery for the treatment of glioblastoma.
TLDR
The rationale, biochemistry, pharmacokinetics, and research history (including toxicity profile) of the BCNU wafers integration into multimodality therapy with the standard Stupp regimen are reviewed. Expand
The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience
TLDR
Median overall survival in 14 studies of newly-diagnosed patients suggested a modest improvement versus resection followed by Stupp protocol or resection with BCNU wafers, with an acceptable and manageable safety profile. Expand
Potential for Nuclear Medicine Therapy for Glioblastoma Treatment
TLDR
The objective of this literature review is to describe the various parameters such as targets, vectors, isotopes, or injection route (systemic and local) in relation to the clinical and preclinical results in glioblastoma pathology. Expand
SPECT imaging and radionuclide therapy of glioma using 131I labeled Buthus martensii Karsch chlorotoxin
TLDR
131I-BmK CT has the potential to be explored as a novel tool for SPECT imaging and radionuclide therapy of glioma and could result in significant tumor inhibition efficacy and prolonging the lifetime of tumor-bearing mice. Expand
Therapeutic options for recurrent malignant glioma.
  • M. Niyazi, A. Siefert, +4 authors C. Belka
  • Medicine
  • Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • 2011
TLDR
The current status of salvage strategies in recurrent high grade glioma is reviewed to review the relative value of each approach compared to other options as it remains open which sequence of modalities should be chosen. Expand
A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG)
TLDR
Radiation therapy demonstrated to be an acceptable option in recurrent HGG with good response rates and acceptable toxicity, and the feasibility and efficacy of re-irradiation in this setting was evaluated. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 26 REFERENCES
Imaging glioma extent with 131I-TM-601.
TLDR
131I-TM-601 provides a reliable estimate for primary tumor extent and further modification of this radiopeptide with other better imaging isotopes may provide an important tool for determining tumors extent and differentiating regions of viable tumor from necrosis. Expand
Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.
TLDR
This study shows that (131)I-mu81C6 mAb increases the median survival of GBM patients and an optimal absorbed dose of 44 Gy to the 2-cm cavity margins is suggested to reduce the incidence of neurologic toxicity. Expand
Radiation dosimetry of 131I-chlorotoxin for targeted radiotherapy in glioma-bearing mice
TLDR
Dosimetry results of 131I-Chlorotoxin in athymic nude mice with intracranially implanted human glioma xenografts and projected radiation doses in patients receiving 370 MBq of 131i-Ch chlorotoxin demonstrated potential in improving patient survival using this novel targeting agent. Expand
Targeted therapy of cancer with radiolabeled antibodies.
  • D. Goldenberg
  • Medicine
  • Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 2002
TLDR
Although RAIT of solid tumors has shown less progress, pretargeting strategies, such as an affinity-enhancement system consisting of bispecific antibodies separating targeting from delivery of the radiotherapeutic, appear to enhance tumor-to-nontumor ratios and may increase rad doses to tumor more selectively than directly labeled antibodies. Expand
Current management of glioblastoma multiforme.
TLDR
Translational research efforts should pursue a broad research agenda until productive avenues are identified to quantify the delivery of novel agents to the malignant brain tumor cells and determine the maximum tolerated dose (MTD) and preliminary efficacy data on novel agents before initiating combination therapies. Expand
Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
TLDR
Tumor-to-normal organ dose ratios were increased about 8- to 11-fold compared with reported patient-specific mean dose and radiation dose to normal organs from circulating radionuclide is substantially reduced using pretargeted RIT. Expand
Influence of sex on toxicity and treatment outcome in small-cell lung cancer.
TLDR
Women experience more chemotherapy-related toxicity in the treatment of SCLC, but they also have increased response rates and survival. Expand
Topographic anatomy and CT correlations in the untreated glioblastoma multiforme.
TLDR
The distribution of cells of a GBM cannot be inferred from CT images since the "peritumoral" area of low density can over- or underestimate the extent of the lesion, and this suggests that glioblastomas will be difficult to treat successfully by intra-arterial therapy using existing therapeutic agents. Expand
Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs).
  • G. Denardo
  • Medicine
  • Seminars in nuclear medicine
  • 2005
TLDR
There is evidence to suggest that the mAb, antigen, radionuclide, chelator, linker, and dosing strategy may make a difference in the outcome of non-Hodgkin's lymphoma. Expand
Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials
TLDR
A small but clear improvement in survival from chemotherapy is shown, which encourages further study of drug treatment of these tumours. Expand
...
1
2
3
...